Smithkline Beecham Corporation

Other

Glaxosmithkline LLC

Cheryl Ann Janson

Xiayang Qiu

Sherin Salaheldin Abdel-Meguid

Ward Whitlock Smith, Jr

Christine Marie Debouck

Zdenka Ludmila Jonak

Kyung Oh Johanson

Narendra B Bam

Robert B Kirkpatrick

Neal Frederick Osborne

Jeffrey S Culp

Xianyang Qiu

Christine Mary Richardson

Ping Yeh

Susan S Hoog

Nestor O Concha

Jacob Bongers

Renee Louise DesJarlais

Richard R Gontarek

Baoguang Zhao

Kyung O Johanson

Jacab S Bongers

Ping-Yang Yeh

Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed.

Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof

AS8 native crystalline structure and aS8 mode of binding with rRNA were identified.

[object Object]

Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.

Conjugates comprising human IL-18 and substitution mutants thereof

A novel human IL-18 native crystalline structure is identified.

Human IL-18 crystal structure

A novel cathepsin K crystalline stucture is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial characteristics.

Method of inhibiting cathepsin K

A novel Staphylococcus glycyl tRNA synthetase crystalline structure is identified. Also disclosed are methods of identifying inhibitors of these synthetases and/or active sites, and inhibitors identified by these methods.

Methods using the staphylococcus aureus glycyl tRNA synthetase crystalline structure

Novel herpes viral protease crystalline structures are identified which have an active site formed by the three amino acids Ser, His and His. Also disclosed are methods of identifying inhibitors of these proteases and/or active sites.

Proteases compositions capable of binding to said site, and methods of

Methods using the Staphylococcus aureus glycyl tRNA synthetase

Proteases, compositions capable of binding to said site, and methods of

Growing community of inventors

Bryn Mawr, PA, United States of America

Cheryl Ann Janson